Navigation Links
Cell transplantation - Potential treatment for blindness

According to a new study, cell transplantation may be a potential treatment for blindness in the elderly people.//

Robert Lanza and Irina Klimanskaya at Advanced Cell Technology, Massachusetts, and Raymond Lund and colleagues at the University of Utah Health Science Centre, carried out the research.

In this study, embryonic stem cells that have the capacity to develop into any of the 200 kinds of cell present in the body were used to enhance eyesight in rats suffering from a disease comparable to age-related macular degeneration.

The study is published in the journal Cloning and Stem Cells. In this study, Retinal pigment epithelium (RPE) was cultured from human embryonic stem cell lines. RPE are the cells that support the light sensing cells in the eye. The cultured RPE was then transplanted into the eyes of a special breed of rat that had an RPE defect, resulting in blindness. It was found that later, the spatial acuity or the capacity to view minute details was restored to up to 70% of that of normal rats.

The research team is hopeful that if similar promising results are obtained in further studies, the treatment may be tried on human beings in 2 years time.
GYT
'"/>




Page: 1

Related medicine news :

1. Stem cell transplantation of eye
2. Stem cell transplantation of eye
3. Importance of type of sex in organ transplantation
4. Xenotransplantation “breakthrough”
5. Down syndrome simulated in animal model after successful chromosome transplantation
6. Hormone therapy for organ transplantation
7. Womb transplantation- to be successful in 2 years’ tim
8. Eyelash transplantation – for the beauty conscious folks!
9. Potential New Cancer Gene Identified
10. Lack of Smell And Its Potential Risks
11. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
Post Your Comments:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 1Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 2Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 4Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 5Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 1Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 2